
Quarterly report 2023-Q2
added 08-02-2023
Conformis Revenue 2011-2026 | CFMS
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Conformis
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 62 M | 99.9 M | 68.8 M | 77.4 M | 89.8 M | 78.1 M | 79.9 M | 66.9 M | 48.2 M | 34.6 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 99.9 M | 34.6 M | 70.6 M |
Quarterly Revenue Conformis
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13 M | 12.8 M | - | 13.8 M | 15.3 M | 15.6 M | - | 14.3 M | 56.3 M | 13.8 M | 16.7 M | 16.1 M | 19.5 M | 16.5 M | 19.9 M | 17.3 M | 19.6 M | 20.6 M | 22 M | 29 M | 19.1 M | 19.7 M | 20.8 M | 18.4 M | 18.5 M | 20.5 M | 21.7 M | 18.6 M | 19.3 M | 20.2 M | 19.1 M | 13.9 M | 19.2 M | 14.7 M | 14.2 M | 12 M | 11.2 M | 10.8 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 56.3 M | 10.8 M | 18.4 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Abiomed
ABMD
|
848 M | - | - | $ 17.2 B | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
AxoGen
AXGN
|
187 M | $ 31.85 | 2.68 % | $ 1.41 B | ||
|
Cognyte Software Ltd.
CGNT
|
443 M | $ 8.97 | -1.59 % | $ 644 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Apyx Medical Corporation
APYX
|
52.3 M | $ 3.89 | -2.51 % | $ 135 M | ||
|
Alphatec Holdings
ATEC
|
612 M | $ 16.95 | -4.48 % | $ 2.42 B | ||
|
Bio-Rad Laboratories
BIO
|
2.57 B | $ 312.8 | -0.23 % | $ 8.83 B | ||
|
CONMED Corporation
CNMD
|
1.31 B | $ 41.19 | -0.91 % | $ 1.27 B | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.69 | -9.12 % | $ 138 M | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 50.26 | 3.85 % | $ 7.49 K | ||
|
Boston Scientific Corporation
BSX
|
16.7 B | $ 91.09 | 3.43 % | $ 134 B | ||
|
Abbott Laboratories
ABT
|
42 B | $ 121.01 | -0.61 % | $ 211 B | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
InMode Ltd.
INMD
|
358 M | $ 13.79 | -1.11 % | $ 1.09 B | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
Electromed
ELMD
|
64 M | $ 27.84 | 0.04 % | $ 235 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Align Technology
ALGN
|
4 B | $ 165.75 | -3.35 % | $ 12.4 B | ||
|
Accuray Incorporated
ARAY
|
459 M | $ 0.81 | -3.78 % | $ 83.2 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
ClearPoint Neuro
CLPT
|
31.4 M | $ 13.82 | -5.67 % | $ 374 M | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 18.68 | 0.24 % | $ 122 M | ||
|
IRadimed Corporation
IRMD
|
73.2 M | $ 102.68 | 0.67 % | $ 1.3 B | ||
|
Integer Holdings Corporation
ITGR
|
1.72 B | $ 84.87 | -1.06 % | $ 2.85 B | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
LivaNova PLC
LIVN
|
1.25 B | $ 62.45 | 0.55 % | $ 3.39 B | ||
|
Globus Medical
GMED
|
2.52 B | $ 92.68 | -0.85 % | $ 12.6 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.61 B | $ 11.98 | -3.51 % | $ 923 M | ||
|
Aziyo Biologics
AZYO
|
24.7 M | - | 1.37 % | $ 20.5 M | ||
|
Pulmonx Corporation
LUNG
|
83.8 M | $ 1.78 | 0.28 % | $ 69.6 M |